AMGN - Amgen - Stock Forecast

Healthcare - Sector
Coverage Profile Performance Price Targets & Ratings Chart

AMGN is currently covered by 20 analysts with an average potential upside of $27.87 (15.74%) from yesterday's end of day stock price of $271.31. Amgen activity chart has currently 402 price targets and 430 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 90.07% with an average time for these price targets to be met of 562.39 days.

Highest price target for AMGN is $287, Lowest price target is $199, average price target is $243.

Most recent stock forecast was given by ROBYN KARNAUSKAS from TRUIST on 29-Nov-2023. First documented stock forecast 29-Jul-2008.

What is Amgen?

Amgen is a biotechnology company that specializes in  developing, manufacturing, and delivering human therapeutics.

The company’s research focuses on six main therapeutic areas, which include inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Products

Amgen produces drugs such as Enbrel, Neulasta, Prolia, Xgeva, Aranesp, KYPROLIS, and Repatha, which treat anemia, cardiovascular disease, multiple myeloma, osteoporosis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.

  • Enbrel
    • Treats inflammatory conditions such as plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. A healthcare provider or the patient injects Enbrel to inhibit tumor necrosis factor (TNF).
  • Neulasta
    • This product reduces the risk of infection in cancer patients undergoing chemotherapy, by stimulating the bone marrow to produce more white blood cells. It is administered by injection, usually 24 hours after chemotherapy.
  • Prolia
    • Treats postmenopausal women with osteoporosis by inhibiting RANKL, a protein involved in bone tissue breakdown. It is given by injection every six months. Prolia can increase bone density and reduce fractures.

History

Amgen was founded in 1980 and is headquartered in Thousand Oaks, California.

Currently, out of the existing stock ratings of AMGN - 41 which are a Buy (43.62%), 46 which are a Hold (48.94%), 7 which are a Sell (7.45%)

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

320

$48.69 (17.95%)

320

11 days ago

27/29 (93.1%)

$54.48 (20.52%)

665

Hold

268

$-3.31 (-1.22%)

250

1 months 8 days ago

7/7 (100%)

$1.41 (0.53%)

101

Hold

291

$19.69 (7.26%)

300

1 months 9 days ago

9/12 (75%)

$30.16 (11.56%)

879

Buy

310

$38.69 (14.26%)

300

1 months 15 days ago

19/29 (65.52%)

$37.84 (13.90%)

580

Buy

310

$38.69 (14.26%)

280

1 months 23 days ago

6/7 (85.71%)

$25.58 (8.99%)

644

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AMGN (Amgen) average time for price targets to be met?

On average it took 562.39 days on average for the stock forecasts to be realized with a an average price target met ratio 90.07

Which analyst has the current highest performing score on AMGN (Amgen) with a proven track record?

DO KIM

Which analyst has the most public recommendations on AMGN (Amgen)?

Do Kim works at PIPER SANDLER and has 46 price targets and 31 ratings on AMGN

Which analyst is the currently most bullish on AMGN (Amgen)?

Robyn Karnauskas with highest potential upside - $48.69

Which analyst is the currently most reserved on AMGN (Amgen)?

Brian Skorney with lowest potential downside - -$98.31

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart